GLPwatch
A Study of LY3457263 in Obese Participants
NCT05582096 · Completed
Last updated 2026-05-28This clinical trial tests the safety of the experimental drug LY3457263 in adults who are overweight or obese.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind basic-science study
Participants 38 people
Who can join Ages 20–70 · all sexes Healthy volunteers accepted.
Timeline Started 2022-11 · est. completion 2023-06
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT05582096 ↗
Description as written by the study sponsor.
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Treatments tested
- LY3457263 Drug
Administered SC.
- Tirzepatide also known as LY3298176 Drug
Administered SC.
- Placebo Drug
Administered SC.
| Main thing measured | Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Overweight, Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05582096 ↗